Patent US5316934A successfully refreshed from Google Patents.
US5316934A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Effective thrombosis mediated by human prourokinase-like polypeptides with increased binding affinity for thrombosis
Assignee: Nippon Soda Co Ltd
•
Filing: 1990-06-07
•
Granted: 1994-05-31
•
Expires: 2010-06-07
Abstract
Abstract Human prourokinase-like polypeptides of which oligopeptides having a structure to form a covalent bond with blood clot (thrombus) through enzymatic action of human blood coagulation factor XIII are attached to the NH 2 -terminal sides of human prourokinase derivatives.
Inventors
- 👤 Yoh-ichi Kobayashi
- 👤 Ken Watabe
- 👤 Yukuo Mukohara
- 👤 Masayuki Satoh
- 👤 Hiroaki Nakamura
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 13:27
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6456; C12N9/6462; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C12Y; C12Y304/00; C12Y304/21; C12Y304/21073; A; A61; A61K; A61K38/00; C07K2319/00; C07K2319/33
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
176 words
A substantially pure, enzymatically-active, human prourokinase mutein comprising a human prourokinase derivative fused with an amino-terminal oligopeptide, said amino-terminal oligopeptide capable of forming a covalent bond with fibrin present in a blood clot through the enzymatic action of human blood coagulation factor XIII, wherein said prourokinase derivative is derived from the amino acid sequence Ser 1 -Leu 411 of human prourokinase and consists essentially of an amino acid sequence selected from the group consisting of Leu 4 -Leu 411 , Leu 4 -Leu 411 in which lysine 135 is substituted with a glutamine residue, Leu 4 -Leu 411 in which lysine 135 and arginine 156 are both substituted with glutamine residues, Leu 4 -Leu 411 in which lysine 135 is substituted with an aspartate residue and arginine 156 is substituted with a glutamine residue, Leu 144 -Leu 411 , and Leu 144 -Leu 411 in which arginine 156 is substituted with a glutamine residue; and, wherein said amino terminal oligopeptide is selected from the group consisting of (Met.)Asn.Gln.Glu.Gln.Val.Ser.Pro.Leu.Thr.Leu.Leu.Lys, (Met.)Gln.Ala.Gln.Gln.Met.Val.Gln.Pro.Gln.Ser.Pro.Val.Ala.Val.Lys, (Met.)Ala.Gln.Lys.Met.Val.Gln.Pro.Leu.Thr.Leu.Leu.Lys, (Met.)Ala.Gln.Lys.Met.Val.Gln.Pro.Gln.Thr.Leu.Leu.Lys, (Met.)Gln.Glu.Gln.Val.Ser.Pro.Gln.Thr.Leu.Leu.Lys, (Met.)Asn.Gln.Asp.Gln.Val.Ser.Pro.Gln.Thr.Leu.Leu.Lys, (Met.)Asn.Gln.Glu.Asn.Val.Ser.Pro.Gln.Thr.Leu.Leu.Lys, and, (Met.)Asn.Gln.Ser.Met.Val.Ser.Pro.Gln.Thr.Leu.Leu.Lys.
Claim 2
Dependent Claim
176 words
A substantially pure, enzymatically-active, human prourokinase mutein comprising a human prourokinase derivative fused with an amino-terminal oligopeptide, said amino-terminal oligopeptide capable of forming a covalent bond with fibrin present in a blood clot through the enzymatic action of human blood coagulation factor XIII, wherein said prourokinase derivative is derived from the amino acid sequence Ser 1 -Leu 411 of human prourokinase and consists essentially of an amino acid sequence selected from the group consisting of Leu 4 -Leu 411 , Leu 4 -Leu 411 in which lysine 135 is substituted with a glutamine residue, Leu 4 -Leu 411 in which lysine 135 and arginine 156 are both substituted with glutamine residues, Leu 4 -Leu 411 in which lysine 135 is substituted with an aspartate residue and arginine 156 is substituted with a glutamine residue, Leu 144 -Leu 411 , and Leu 144 -Leu 411 in which arginine 156 is substituted with a glutamine residue; and, wherein said amino terminal oligopeptide is selected from the group consisting of (Met.)Asn.Gln.Glu.Gln.Val.Ser.Pro.Leu.Thr.Leu.Leu.Lys, (Met.)Gln.Ala.Gln.Gln.Met.Val.Gln.Pro.Gln.Ser.Pro.Val.Ala.Val.Lys, (Met.)Ala.Gln.Lys.Met.Val.Gln.Pro.Leu.Thr.Leu.Leu.Lys, (Met.)Ala.Gln.Lys.Met.Val.Gln.Pro.Gln.Thr.Leu.Leu.Lys, (Met.)Gln.Glu.Gln.Val.Ser.Pro.Gln.Thr.Leu.Leu.Lys, (Met.)Asn.Gln.Asp.Gln.Val.Ser.Pro.Gln.Thr.Leu.Leu.Lys, (Met.)Asn.Gln.Glu.Asn.Val.Ser.Pro.Gln.Thr.Leu.Leu.Lys, and, (Met.)Asn.Gln.Ser.Met.Val.Ser.Pro.Gln.Thr.Leu.Leu.Lys.
Claim 3
Dependent Claim
37 words
An isolated and purified DNA segment consisting essentially of a region encoding a human prourokinase mutein of claim 1 an allelic variant or exhibiting equivalent biological activity, capable of hybridizing therewith under conditions allowing detection of 70%.
Claim 4
Dependent Claim
35 words
DNA segment of claim 2 further comprising a transcriptional promoter element in operable linkage with said region encoding a human prourokinase mutein, said promoter element useful as a promoter of gene expression in E. coli.
Claim 5
Dependent Claim
23 words
A DNA construct comprising a DNA sequence of claim 2 and a replication system capable of replication in an E. coli host cell.
Claim 6
Dependent Claim
35 words
A recombinant plasmid comprising a DNA sequence of claim 2 wherein said plasmid is a cloning vehicle and is capable of expressing a DNA sequence of claim 2 in a transformed E. coli host cell.
Claim 7
Dependent Claim
10 words
E. coli transformed with the plasmid according to claim 5.
Claim 8
Dependent Claim
28 words
The E. coli transformants of the DNA construct of claim 4 selected from the E. coli strain transformants consisting essentially of FERM BP-2467, FERM BP-2465, and FERM BP-2466.
References Cited (Backward Citations)
EP0271227A2
Cited
WO1988003810A1
Cited
EP0273774A2
Cited
WO1989000051A1
Cited
EP0312942A2
Cited
US4892826A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-05-30 | 1997-11-29 | 1998-05-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-05-30 | 2001-11-29 | 2002-05-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-05-30 | 2005-11-29 | 2006-05-31 | $7700.00 | Window Closed / Lapsed |